| Autor: |
Yılmaz, Resul, Karaaslan, Erhan, Gül, Ali, Albayrak, Süleyman Ekrem, Kasap, Tuba |
| Předmět: |
|
| Zdroj: |
Erciyes Medical Journal / Erciyes Tip Dergisi; Mar2018, Vol. 40 Issue 1, pS16-S16, 1/2p |
| Abstrakt: |
Introduction: In this study, it was aimed to evaluate the admission profile, treatments and outcomes of the CCHF patients admitted to the Pediatric Intensive Care Unit (PICU). Material and method: Between January 2014 and August 2016, the data of CCHF patients admitted to Gaziosmanpasa University Medical Faculty Hospital, were retrospectively obtained from the hospital information system. Results: 123 Crimean-Congo hemorrhagic fever suspected patients were directly admitted or referred to hospital, 22 cases of CCHF were admitted to PICU. Seven of the patients (32%) were female and 21 (95.5%) were living in the rural area. In 16 patients, the tick was removed either by the patient or his/her relatives, the ticks were removed by healthcare personnel in only 2 patients and 3 patients had no tick contact. The most common symptoms were fever 21 (95.5%), myalgia 21 (95.5%), headache 18 (81.8%), and bleeding 17 (77.3%). Patients received an average of 5 units of platelet suspension, 3 units of Fresh frozen plasma when indicated. 12 patients (54.5%) had 3-10 days of hospital stay and only 14 patients (63.6%) had ribavirin use. Mortality rate was determined as 0. Conclusion: Transfusing thrombocyte suspensions with targetting upper values of thrombocyte as above 40,000/mm3 will be life-saving in the fight against this mortal disease whose lethal complication is bleeding. Although the use of ribavirin was recommended by WHO, there was no difference in terms of morbidity and mortality in cases whom ribavirin was not administered because of side effects and allergies. There is a need for randomized controlled trials of prophylactic transfusion and ribavirin use in CCHF. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
